SCHEMBL7832010

SCHEMBL7832010

[CH2]c1ccc(NC(=O)C(C)(C)c2ccccc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.66
HDAC1 Q13547 2/20 0.66
HDAC4 P56524 1/20 0.66
HDAC7 Q8WUI4 1/20 0.66
HDAC2 Q92769 1/20 0.66
HDAC10 Q969S8 1/20 0.66
HDAC11 Q96DB2 1/20 0.66
HDAC8 Q9BY41 1/20 0.66
HDAC6 Q9UBN7 1/20 0.66
HDAC9 Q9UKV0 1/20 0.66
HDAC5 Q9UQL6 1/20 0.66
NPY2R P49146 5/20 0.53
NCOR2 Q9Y618 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.48
RORC P51449 1/20 0.48
ELOVL1 Q9BW60 1/20 0.47
LMNA P02545 1/20 0.46
PDK1 Q15118 2/20 0.46
PDK2 Q15119 2/20 0.46
PDK3 Q15120 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4965466 0.88 HDAC3 (0.71) HDAC3HDAC1HDAC4HDAC7HDAC2
SCHEMBL28465548 0.83 HDAC3 (0.75) HDAC3HDAC1HDAC4HDAC7HDAC2
SCHEMBL7835891 0.81 HDAC3 (0.63) HDAC3HDAC1HDAC4HDAC7HDAC2
SCHEMBL22185077 0.81 HDAC3 (0.62) HDAC3HDAC1HDAC4HDAC7HDAC2
SCHEMBL673402 0.80 HDAC6 (1.00) HDAC3HDAC1HDAC4HDAC7HDAC2
SCHEMBL31155744 0.78 KMT2A (0.59) HDAC3HDAC1HDAC4HDAC7HDAC2
SCHEMBL6708273 0.78 L3MBTL1 (0.79) L3MBTL1LMNAKMT2AMAPTMEN1
SCHEMBL18612662 0.78 HDAC3 (0.63) HDAC3HDAC1HDAC4HDAC7HDAC2
SCHEMBL1442226 0.74 HDAC3 (0.54) HDAC3HDAC1HDAC4HDAC7HDAC2
SCHEMBL676042 0.73 HDAC1 (0.75) HDAC3HDAC1HDAC4HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0676398-B1 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO CO (JP) 2001-10-24 EP disclosed
US-6117893-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 2000-09-12 US disclosed
US-5977365-A HYPOGLYCEMIC AGENTS SANKYO COMPANY, LIMITED (JP) 1999-11-02 US disclosed
US-5962470-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 1999-10-05 US disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
US-5834501-A TREATING DIABETES OR HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1998-11-10 US disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 US disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 EP disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed